🔍

Amrutanjan Health Care Limited (AMRUTANJAN)

📊 NSE: AMRUTANJAN 🏢 Pharmaceuticals - Indian - Formulations 📅 Last Updated: 12/13/2025 18:18

📢 Recent Corporate Announcements

Amrutanjan Submits FY26 BRSR and Annual Report Disclosures

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 28 Aug 2026, 01:43 PM

Amrutanjan Health Care Limited has submitted its Business Responsibility and Sustainability Report (BRSR) along with its Annual Report for FY 2025-26. In the report, the Chairman highlighted 11% revenue growth and 25% profit growth (before exceptional items) for the year, led by pain management and the Comfy women's hygiene brand. The company expanded its presence to 14 countries and broadened its product portfolio into ortho pain, personal care, and nasal care. This filing represents a routine statutory compliance submission under SEBI LODR Regulations.

Delivered 11% revenue growth and 25% profit growth (before exceptional items) in FY2026
Reported double-digit gross sales growth across core pain management and women's hygiene segments
Expanded geographic reach across 14 countries spanning 4 continents
Launched new product offerings across ortho pain, nasal care, and personal care segments in FY2026

💡 Track the execution and market uptake of newly introduced lines (ortho pain, nasal care) and volume scaling at upcoming quarterly results.

Amrutanjan Convenes 89th AGM on Sept 23, 2026; Submits FY26 Annual Report

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 28 Aug 2026, 01:37 PM

Amrutanjan Health Care Limited has submitted its 89th Annual Report for FY2025-26 and scheduled its Annual General Meeting (AGM) for September 23, 2026, through video conferencing. The report highlights double-digit gross sales growth in pain management and women's hygiene portfolios during FY2026, supported by geographic expansion across 14 countries. The statutory auditor included a standard technical observation regarding daily electronic backups for payroll and specific billing modules not being physically hosted in India.

89th Annual General Meeting to be held on Wednesday, September 23, 2026, at 10:30 AM via VC/OAVM
Company expanded its distribution footprint across 14 countries and 4 continents
Reported double-digit gross sales growth in core pain management and women's hygiene categories for FY2026
Auditor noted an observation on electronic book-keeping backups for payroll not stored on servers located physically in India

💡 Track resolutions and management commentary during the AGM on September 23, 2026, regarding the ramp-up of the Hyderabad Comfy manufacturing plant and new product performance.

9.5% Revenue Growth in Q1 FY27; Rs 150 Cr New Plant Commissioned for Comfy

🟡 NEUTRAL ⭐ 7/10

EARNINGS 📅 12 Aug 2026, 08:35 PM

Amrutanjan reported a 9.48% YoY increase in net sales to Rs 102.97 Cr for Q1 FY27, driven by strong performance in the Women's Hygiene segment. However, Profit After Tax (PAT) declined to Rs 4.37 Cr from Rs 8.31 Cr YoY, impacted by a Rs 2.02 Cr exceptional item related to a legacy lease dispute and increased advertisement spending (Rs 7.81 Cr). A major strategic milestone was the commissioning of a Rs 150 Cr greenfield plant in Telangana for the 'Comfy' brand, shifting production from private-label to in-house. Management maintains a double-digit growth outlook for the full year as one-time charges subside.

Net Sales grew 9.48% YoY to Rs 102.97 Cr in Q1 FY27.
Commissioned a Rs 150 Cr greenfield sanitary napkin facility in Telangana, representing ~35% of TTM revenue.
Women's Hygiene (Comfy) revenue grew 18.14% YoY to Rs 33.80 Cr, now contributing 33% of total sales.
Recognized an exceptional charge of Rs 2.02 Cr for a legacy lease rent dispute settled in August 2026.
New product launches (Razors and Plastry) contributed Rs 4.12 Cr to Q1 sales, with a full-year target of Rs 25 Cr.

💡 Monitor the capacity utilization and margin profile of the new Telangana plant, and watch for a recovery in the core Pain Management segment which saw flat growth (+0.51%) this quarter.

Amrutanjan sets September 11, 2026, as Record Date for FY26 Final Dividend

🟡 NEUTRAL ⭐ 4/10

DIVIDEND 📅 11 Aug 2026, 06:32 PM

Amrutanjan Health Care Limited has officially fixed September 11, 2026, as the record date for its final dividend for the financial year 2025-26. This procedural announcement follows a fiscal year where the company reported a net profit of ₹16.19 crore on a revenue of ₹290.81 crore. The dividend will be paid to shareholders whose names appear in the register of members or as beneficial owners in NSDL/CDSL records as of the record date. While the specific dividend amount per share is not disclosed in this filing, it represents the final payout for the FY26 period.

Record date for final dividend payment fixed for September 11, 2026
Dividend pertains to the full financial year 2025-26 performance
Company reported FY26 revenue of ₹290.81 crore
FY26 Net Profit stood at ₹16.19 crore with an operating margin of 16.91%
Eligibility determined by beneficial ownership records from NSDL and CDSL

💡 Investors should note the record date of September 11, 2026; to be eligible for the dividend, shares must be purchased before the ex-dividend date (typically one business day prior). No further action is required for existing shareholders.

Amrutanjan Q1 PAT Rises 46% to ₹4.37 Cr; Women's Hygiene Segment Grows 27% YoY

🟢 POSITIVE ⭐ 7/10

EARNINGS 📅 11 Aug 2026, 06:25 PM

Amrutanjan Health Care reported a 9.5% YoY increase in revenue to ₹102.97 Cr for the quarter ended June 30, 2026. Net profit grew significantly by 46.6% YoY to ₹4.37 Cr, despite an exceptional charge of ₹2.03 Cr related to a retrospective lease rent dispute. Growth was primarily driven by the Women's Hygiene segment, which surged 27% to ₹36.36 Cr, while the core OTC segment remained nearly flat at ₹57.26 Cr. The company has set September 11, 2026, as the record date for the final dividend.

Revenue from operations increased 9.5% YoY to ₹102.97 Cr from ₹94.05 Cr.
Net Profit (PAT) grew 46.6% YoY to ₹4.37 Cr despite a ₹2.03 Cr exceptional item.
Women's Hygiene segment revenue rose to ₹36.36 Cr, now contributing ~35% of total revenue.
Core OTC segment revenue showed marginal growth of 0.5% YoY, reaching ₹57.26 Cr.
Exceptional item of ₹2.03 Cr recognized following a demand notice from the HR & CE Department regarding leasehold land.

💡 Watch for the margin impact as the company transitions 'Comfy' production to its in-house Hyderabad plant. Investors should also monitor if the core OTC segment can regain volume momentum in upcoming quarters.

₹150 Cr Investment: Amrutanjan Commissions New 700M Unit Sanitary Napkin Plant in Telangana

🟢 POSITIVE ⭐ 8/10

EXPANSION 📅 05 Aug 2026, 12:36 PM

Amrutanjan Health Care has commissioned a new ₹150 crore greenfield manufacturing facility in Telangana, dedicated to its 'Comfy' sanitary napkin brand. The plant features two high-speed Japanese production lines with an annual capacity of 700 million units, marking a strategic shift from private-label outsourcing to in-house manufacturing. This investment is significant, representing approximately 40.5% of the company's current net worth (₹370 Cr). The move aims to support the Comfy brand, which already surpassed ₹130 crore in revenue during FY2025.

₹150 crore total investment in the new greenfield facility at Seetharampur, Telangana.
700 million sanitary napkins annual production capacity across two automated Japanese lines.
1.4 lakh sq. ft. built-up area on a 10-acre site, serving as the company's 5th plant.
Strategic transition from private-label partnerships to in-house production for the Comfy brand.
Comfy brand revenue already exceeded ₹130 crore in FY2025 prior to this expansion.

💡 Monitor operating profit margins (OPM) in the coming quarters to see if the shift to in-house manufacturing improves the current 11.5% margin. Investors should also track the utilization rate of the new 700 million unit capacity relative to sales growth in the feminine hygiene segment.

CARE Assigns 'CARE A; Stable' Rating to Amrutanjan; Highlights Debt-Free Status

🟢 POSITIVE ⭐ 6/10

REGULATORY 📅 05 Aug 2026, 12:17 PM

CARE Ratings has assigned a 'CARE A; Stable' issuer rating to Amrutanjan Health Care Limited, reflecting its 133-year brand legacy and debt-free balance sheet. The company reported a Total Operating Income of ₹502.55 Cr in FY26 with a strong cash and bank balance of ₹221.85 Cr. While the core pain management segment contributes 60% of revenue, the company is diversifying into women's hygiene and beverages. A significant ₹130 Cr investment in a new Hyderabad manufacturing plant for sanitary napkins became operational in June 2026, aimed at improving margins through in-house production.

Assigned 'CARE A; Stable' issuer rating by CARE Ratings Limited.
Maintains a debt-free capital structure with a net worth of ₹368.78 Cr as of March 31, 2026.
Total Operating Income grew 11% to ₹502.55 Cr in FY26 compared to FY25.
Invested ₹130 Cr in a new sanitary napkin plant in Hyderabad, funded entirely by internal accruals.
Cash and bank balances including deposits stood at ₹221.85 Cr as of March 31, 2026.

💡 Investors should monitor the margin trajectory of the 'Comfy' hygiene brand now that in-house production has commenced at the Hyderabad plant. The key metric to watch is whether the company can successfully scale its non-pain relief segments beyond the current 40% revenue share.

Rs 9.75 Cr lease rent arrears paid by Amrutanjan following Madras High Court order

🔴 NEGATIVE ⭐ 6/10

LEGAL 📅 01 Aug 2026, 07:37 PM

Amrutanjan Health Care has paid Rs 9.75 crore in lease rent arrears to the Kapaleeswarar Temple following a dismissal of its writ petition by the Madras High Court. This payment settles a long-standing legal dispute regarding the Tamil Nadu Hindu Religious and Charitable Endowment Act 1959. The outflow is significant, representing approximately 61% of the company's TTM Net Profit of Rs 16 crore. While the company states there is no significant impact on operations, the one-time charge will likely weigh on the immediate quarter's profitability.

Total payment of Rs 9,74,67,151 made to Kapaleeswarar Temple on August 1, 2026.
The payment follows a Madras High Court order dated March 17, 2026, which dismissed the company's appeal.
The arrears amount represents approximately 61% of the company's TTM Net Profit (Rs 16 Cr).
The court-mandated deadline for the payment was August 2, 2026.
The dispute originated from Writ Petition No. 35484 of 2005 regarding lease rent regulations.

💡 Investors should monitor the next quarterly financial results to see if this Rs 9.75 Cr is classified as an 'exceptional item' and how it impacts the cash flow statement.

Regulation 74(5) Compliance Certificate Submitted for Quarter Ended June 30, 2026

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 08 Jul 2026, 10:18 AM

Amrutanjan Health Care Limited has submitted its quarterly compliance certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018. The document, dated July 8, 2026, confirms that the Registrar and Share Transfer Agent (RTA), Cameo Corporate Services Limited, has processed all dematerialization requests for the quarter ended June 30, 2026. The RTA verified that physical certificates were mutilated and cancelled, and the depository's name was updated in the register of members. This is a standard procedural filing required by all listed companies to ensure the integrity of shareholding records.

Compliance certificate issued for the quarter ended June 30, 2026
Registrar and Share Transfer Agent (RTA) confirmed processing of dematerialization requests within stipulated time limits
Physical security certificates were mutilated and cancelled after due verification
The filing was submitted to the exchanges on July 08, 2026

💡 This is a routine administrative filing; investors should monitor the upcoming Q1 FY27 earnings release for fundamental business updates and operational performance.

Amrutanjan Health Care Announces Trading Window Closure from July 1, 2026

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 24 Jun 2026, 04:52 PM

Amrutanjan Health Care Limited has informed the exchanges that its trading window for dealing in company securities will be closed starting July 1, 2026. This closure is in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015, ahead of the upcoming quarterly financial results. The window will remain closed for all designated persons until 48 hours after the declaration of the unaudited financial results for the quarter ending June 30, 2026. This is a standard regulatory procedure followed by listed companies to prevent insider trading before earnings announcements.

Trading window closure effective from July 1, 2026.
Closure pertains to the unaudited financial results for the quarter ending June 30, 2026.
Window to reopen 48 hours after the official announcement of financial results.
Applicable to all Designated Persons as per the Company's Code of Conduct.
Complies with SEBI (Prohibition of Insider Trading) Regulations, 2015.

💡 No action is required as this is a routine regulatory filing. Investors should await the announcement of the quarterly results date for further performance insights.

Amrutanjan Shareholders Approve Appointment and Re-appointment of Independent Directors

🟡 NEUTRAL ⭐ 4/10

MANAGEMENT 📅 19 Jun 2026, 06:47 PM

Amrutanjan Health Care Limited has announced the results of its postal ballot, where shareholders approved two key board appointments. Dr. Ramaswami Krishnan has been appointed as a Non-Executive Independent Director for a five-year term. Additionally, Mr. Swayambunathan Muralidharan was re-appointed for a second five-year term as a Non-Executive Independent Director. Both resolutions were passed as Special Resolutions with the requisite majority, ensuring board stability and governance continuity.

Appointment of Dr. Ramaswami Krishnan as Non-Executive Independent Director for a 5-year term.
Re-appointment of Mr. Swayambunathan Muralidharan for a second 5-year term as Independent Director.
Both appointments were approved as Special Resolutions, requiring at least 75% shareholder support.
The outcome follows the postal ballot process initiated via notice on May 18, 2026.

💡 No immediate action is required as these are routine governance-related board appointments. Investors should view this as a standard procedure to maintain regulatory compliance and board oversight.

Amrutanjan Shareholders Approve Director Appointments with Over 99.7% Majority

🟡 NEUTRAL ⭐ 4/10

MANAGEMENT 📅 19 Jun 2026, 06:41 PM

Amrutanjan Health Care Limited has announced the successful passage of two special resolutions via postal ballot. Shareholders approved the appointment of Dr. Ramaswami Krishnan as a Non-Executive Independent Director for five years with 99.99% votes in favor. Additionally, the re-appointment of Mr. Swayambunathan Muralidharan for a second five-year term was confirmed with 99.80% approval. A total of 15,869,989 votes were polled, representing 54.89% of the total outstanding shares.

Dr. Ramaswami Krishnan appointed as Non-Executive Independent Director for a 5-year term ending May 2031.
Mr. Swayambunathan Muralidharan re-appointed for a second 5-year term as Non-Executive Independent Director.
Total valid votes cast amounted to 15,869,989, with a high consensus of over 99.7% for both resolutions.
The voting process saw participation from 228 shareholders via remote e-voting between May 19 and June 18, 2026.
Both resolutions were passed as Special Resolutions, ensuring board continuity and regulatory compliance.

💡 No immediate action is required as these are routine governance appointments. The high approval ratings reflect strong shareholder confidence in the current board's composition.

Amrutanjan Health Care Reconstitutes Board Committees; Ramaswami Krishnan Appointed Audit Chair

🟡 NEUTRAL ⭐ 3/10

MANAGEMENT 📅 27 May 2026, 06:00 PM

Amrutanjan Health Care Limited has announced the reconstitution of several board committees following the departure of Director Mr. Raja Venkataraman. Mr. Ramaswami Krishnan has been appointed to fill the vacancies, most notably taking over as the Chairman of the Audit Committee. He will also serve as a member of the Corporate Social Responsibility and Risk Management Committees. This transition ensures continuity in the company's governance and oversight functions.

Mr. Raja Venkataraman has ceased to be a Director of the company.
Mr. Ramaswami Krishnan appointed as the new Chairman of the Audit Committee.
Mr. Ramaswami Krishnan joins the Corporate Social Responsibility Committee as a member.
Mr. Ramaswami Krishnan joins the Risk Management Committee as a member.

💡 This is a routine governance update and does not impact the company's fundamentals. Investors should continue to monitor the company's quarterly performance and broader healthcare sector trends.

Amrutanjan Health Care: Independent Director Raja Venkataraman Completes Term

🟡 NEUTRAL ⭐ 3/10

MANAGEMENT 📅 26 May 2026, 09:26 PM

Amrutanjan Health Care Limited has announced that Mr. Raja Venkataraman (DIN: 00669376) has completed his first term as an Independent Director. Consequently, he ceased to be a director of the company effective from the close of business hours on May 26, 2026. This is a routine transition following the completion of a fixed tenure as per SEBI regulations. The company has expressed appreciation for his contributions during his tenure.

Mr. Raja Venkataraman (DIN: 00669376) completed his first term as Independent Director.
Cessation of directorship effective from close of business hours on May 26, 2026.
The vacancy occurred due to the completion of the prescribed tenure under SEBI regulations.
Disclosure made in compliance with Regulation 30 of SEBI (LODR) Regulations, 2015.

💡 This is a routine governance update with no impact on business operations. Investors should monitor for the appointment of a new independent director to ensure the board remains compliant with regulatory standards.

Amrutanjan Health Care Seeks Shareholder Approval for Director Appointments via Postal Ballot

🟡 NEUTRAL ⭐ 4/10

MANAGEMENT 📅 19 May 2026, 05:51 PM

Amrutanjan Health Care Limited has issued a Postal Ballot notice to seek shareholder approval for two key board appointments. The company proposes the appointment of Mr. Ramaswami Krishnan as a Non-Executive Independent Director for a five-year term ending May 7, 2031. Additionally, it seeks the re-appointment of Mr. Swayambunathan Muralidharan for a second five-year term starting June 29, 2026. The e-voting process is scheduled to take place between May 19, 2026, and June 18, 2026, with results expected by June 22, 2026.

Proposed appointment of Mr. Ramaswami Krishnan as Independent Director for a 5-year term until May 2031.
Proposed re-appointment of Mr. Swayambunathan Muralidharan for a second 5-year term starting June 29, 2026.
Remote e-voting period spans 30 days from May 19, 2026, to June 18, 2026.
The cut-off date for determining shareholder eligibility to vote was May 15, 2026.
Both resolutions are classified as Special Resolutions requiring a 75% majority for approval.

💡 Investors should review the professional backgrounds of the proposed directors to ensure they support the company's governance standards and cast their votes before the June 18 deadline.

View All AMRUTANJAN Announcements on Live Market Tracking →

💰 Financial Performance

Revenue Growth by Segment

In FY2025, the OTC segment grew 5.41% to INR 290.03 Cr, the Comfy segment grew 17.77% to INR 123.96 Cr, and the Beverages segment declined 8.88% to INR 36.43 Cr. For H1 FY2026, total Net Sales reached INR 211.75 Cr, a 9.35% YoY increase.

Geographic Revenue Split

Not disclosed in available documents, though the company identifies 'P3' markets as areas with currently low penetration and high competition.

Profitability Margins

Operating profit margin improved from 10.86% in FY2024 to 11.44% in FY2025. Net profit margin increased from 10.68% to 11.25% over the same period. For H1 FY2026, Profit After Tax (PAT) grew 35.71% YoY to INR 22.27 Cr.

EBITDA Margin

EBITDA margin for FY2025 was 12.88%, up from 12.30% in FY2024, representing an absolute EBITDA of INR 58.20 Cr, a 12.33% YoY growth.

Capital Expenditure

The company is developing a state-of-the-art manufacturing plant for sanitary napkins in Hyderabad to meet anticipated market demand and ensure long-term scalability. Specific INR Cr values for the project were not disclosed.

Credit Rating & Borrowing

Not disclosed in available documents; however, the company reported negligible interest costs of INR 0.22 Cr in FY2025, suggesting a debt-free or low-leverage status.

⚙️ Operational Drivers

Raw Materials

Key raw materials include menthol, chemicals, and packaging materials. In FY2025, cost of materials consumed was INR 223.21 Cr, representing 49.40% of net sales.

Capacity Expansion

The company is currently expanding capacity by setting up a dedicated manufacturing plant for Comfy sanitary napkins in Hyderabad to transition from a private-label partnership to in-house production.

Raw Material Costs

Raw material costs represented 49.40% of net sales in FY2025. In H1 FY2026, raw material prices were reported as higher than H1 FY2025, while packing material prices were lower.

📈 Strategic Growth

Expected Growth Rate

9.35%

Growth Strategy

Growth will be driven by the new Hyderabad manufacturing plant for Comfy to scale women's hygiene revenue, which already crossed INR 130 Cr in FY2025. The company is also targeting 'P3' markets for deeper penetration, expanding D2C and e-commerce channels, and launching new products like Electro Plus in the beverages category.

Products & Services

Pain management balms and roll-ons, Comfy sanitary napkins, Fruitnik fruit juices, and Electro Plus electrolyte drinks.

Brand Portfolio

Amrutanjan, Comfy, Fruitnik, Electro Plus.

New Products/Services

New product launches include Electro Plus in the beverages segment. The Comfy brand is expected to contribute significantly following the commencement of the new Hyderabad plant.

Market Expansion

Expansion plans focus on 'P3' markets where penetration is currently low and scaling up distribution through new super stockists and sub-stockists.

Market Share & Ranking

Not disclosed in available documents, but the company notes that 62% of its revenue is derived from the Head and Body pain management categories.

Strategic Alliances

The company previously utilized a successful private label partnership for Comfy sanitary napkins, which is now being transitioned to in-house manufacturing.

🌍 External Factors

Industry Trends

The health and wellness market in India is growing, with a shift toward specialized hygiene and electrolyte products. Amrutanjan is positioning itself by diversifying from its core pain balm into women's hygiene and functional beverages.

Competitive Landscape

Faces strong competition in rural and P3 markets from both national and local players in the OTC and hygiene segments.

Competitive Moat

The company's moat is built on the strong brand equity of 'Amrutanjan' in the pain management sector, where it holds a dominant position in the Head and Body categories (62% of revenue). This brand recall is sustainable due to long-term consumer trust and a growing distribution network.

Macro Economic Sensitivity

Highly sensitive to monsoon performance, which affects raw material input costs, and major political or economic changes in India.

Consumer Behavior

Evolving consumer needs are driving demand for specialized products in the hygiene and wellness categories, prompting the company to launch new variants and functional drinks.

⚖️ Regulatory & Governance

Industry Regulations

Operations are subject to changes in regulatory compliances and manufacturing standards, which the company identifies as a potential threat to its business plans.

Taxation Policy Impact

The effective tax rate for FY2025 was approximately 26.47%, with tax expenses of INR 18.30 Cr on a PBT of INR 69.13 Cr.

⚠️ Risk Analysis

Key Uncertainties

Key risks include monsoon failure (impacting input costs), low penetration in P3 markets, and volatility in packaging material prices which could impact margins by 5-10%.